George Fromm
Chief Scientific Officer KAYAK
George is the scientific founder and Chief Scientific Officer of Kayak Therapeutics, as well as the inventor of its lead technology. Previously, he was the scientific co-founder of Shattuck Labs, where he served as CSO and led the oncology preclinical pipeline development efforts that resulted in multiple clinical-stage programs and several hundred pipeline candidates. Previously, George served as the Senior Director of Research and Development at Heat Biologics, Inc., where he directed the Discovery and Clinical research efforts for their phase I/II trials. He received his M.S. and Ph.D. from the University of Rochester, NY, and conducted his post-doctoral fellowship training with the NIH branch, the National Institute of Environmental Health Sciences.
Seminars
- KT-300 is a covalent small molecule inhibitor of the E3 ubiquitin ligase TRIM7, which is hyperactivated in RTK/RAS driven cancers, enabling broad activity across tumor types and offering a potential path beyond mutation-specific targeting strategies
- KT-300 is active in the setting of KRAS inhibitor resistance, and may support sustained pathway suppression and improve the potential for durable responses in RAS-driven cancers
- Combined blockade with KT-300 and upstream RAS-pathway inhibition (e.g.; anti- EGFR, KRASi, etc.) enhance anti-tumor responses, creating broad opportunities for rationale combinations
